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Distinct colicin M-like bacteriocin-
immunity pairs in Burkholderia
Maarten G. K. Ghequire & René De Mot
The Escherichia coli bacteriocin colicin M (ColM) acts via degradation of the cell wall precursor lipid 
II in target cells. ColM producers avoid self-inhibition by a periplasmic immunity protein anchored in 
the inner membrane. In this study, we identified colM-like bacteriocin genes in genomes of several 
β-proteobacterial strains belonging to the Burkholderia cepacia complex (Bcc) and the Burkholderia 
pseudomallei group. Two selected Burkholderia ambifaria proteins, designated burkhocins M1 and 
M2, were produced recombinantly and showed antagonistic activity against Bcc strains. In their 
considerably sequence-diverged catalytic domain, a conserved aspartate residue equally proved 
pivotal for cytotoxicity. Immunity to M-type burkhocins is conferred upon susceptible strains by 
heterologous expression of a cognate gene located either upstream or downstream of the toxin 
gene. These genes lack homology with currently known ColM immunity genes and encode inner 
membrane-associated proteins of two distinct types, differing in predicted transmembrane topology 
and moiety exposed to the periplasm. The addition of burkhocins to the bacteriocin complement 
of Burkholderia reveals a wider phylogenetic distribution of ColM-like bacteriotoxins, beyond 
the γ-proteobacterial genera Escherichia, Pectobacterium and Pseudomonas, and illuminates the 
diversified nature of immunity-providing proteins.
Burkholderia is a common soil inhabitant and exhibits attractive properties such as degradation of envi-
ronmental pollutants, production of bioactive secondary metabolites and biocontrol of phytopathogenic 
fungi1–3. Conversely, this β -proteobacterial genus includes phytopathogenic species and some members 
also pose a major threat to animal and human health. The Burkholderia pseudomallei group includes 
B. pseudomallei, the causative agent of melioidosis, and Burkholderia mallei, giving rise to glanders4,5. 
Another group, comprising several phylogenetically closely related Burkholderia species, constitutes the 
Burkholderia cepacia complex (Bcc) and these opportunistic pathogens frequently colonize lungs of 
cystic fibrosis and immunocompromised patients2,6,7. Therapeutic options against these pathogens are 
scarce, urgently requiring the development of novel antibacterials. Of particular interest are antagonis-
tic compounds with narrow-spectrum of activity in order to minimize collateral damage to beneficial 
microbiota.
One possible strategy to identify new Burkholderia-specific therapeutics is to exploit the antibacterial 
arsenal encoded in Burkholderia’s own genomes. Evidence for specific antagonism between Burkholderia 
strains has been reported8,9, but few compounds mediating such interactions have been characterized: 
enacyloxin, a polyketide antibiotic from Burkholderia ambifaria AMMD10; capistruin, a ribosomally 
encoded lasso peptide from Burkholderia thailandensis E26411; the plant lectin-like protein LlpA from 
Burkholderia cenocepacia AU105412; and a tailocin complex from B. cenocepacia BC042513,14. Another 
mechanism mediating antibiosis is contact-dependent inhibition, demonstrated in B. thailandensis and 
B. pseudomallei. There, toxic domains are directed to target cells via two-partner secretion15,16.
Contrary to Burkholderia, the genus-specific bacteriotoxic armamentarium of γ -proteobacteria has 
been studied in much more detail, with colicins from Escherichia coli17 and pyocins from Pseudomonas 
aeruginosa serving as prominent model systems18. Colicin M (ColM) is one such well-characterized 
bacteriocin taking advantage of the FhuA outer membrane siderophore transporter as a receptor 
and highjacking the TonB/ExbB/ExbD machinery for further translocation via an amino-terminal 
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TonB-interacting box19,20. Inhibitory action is mediated by phosphatase activity that cleaves lipid II 
peptidoglycan precursors, releasing undecaprenol and pyrophosphoryl groups21,22. Immunity is pro-
vided by a downstream-located gene, transcribed in opposite direction, that encodes a cytoplasmic 
membrane-anchored immunity protein (ColM immunity protein, Cmi), facing the periplasmic space and 
protecting the producer cells via an unknown mechanism23,24. The Cmi monomer is composed of four β 
strands and four α helices and requires an intramolecular disulfide bond to be functional25. Interestingly, 
Usón et al.26 reported dimerization via domain swapping of a significant fraction of Cmi proteins, sta-
bilization between the two monomers being provided by two intermolecular disulfide bridges. The Cmi 
fold is exemplary for YebF family proteins that require OmpF for their secretion27. YebF appears as a 
monomer with an intramolecular disulfide bond.
ColM-like bacteriocins have also been characterized in two other γ -proteobacterial genera: 
Pseudomonas28–30 and Pectobacterium31. A putative immunity gene sharing homology with cmi was pre-
dicted for pectocin M1 in Pectobacterium carotovorum PC1, showing the same gene organization as 
colM-cmi31. To date, no cmi-like immunity genes have been retrieved in Pseudomonas30.
In this work we purified and characterized two ColM-like proteins from the Bcc species B. ambi-
faria, killing target cells with genus-specific activity. These proteins display a similar domain composi-
tion as γ -proteobacterial ColM-type bacteriocins although their catalytic domains are poorly conserved. 
The toxin genes are associated with one of two novel types of genes which provide bacteriocin-specific 
immunity.
Results
ColM-like bacteriocin genes in Burkholderia genomes. Genomic homology searches in the 
β -proteobacterial genus Burkholderia, using ColM domains (Pfam PF14859) of functionally character-
ized ColM-type bacteriocins from E. coli, Pectobacterium and Pseudomonas as queries, revealed several 
uncharacterized proteins encoded by 16 strains (Table  1). These proteins almost exclusively occur in 
Bcc strains, although two representatives were detected in Burkholderia oklahomensis, member of the 
Pseudomallei group. Among these proteins, further termed burkhocin M (BurM), the catalytic domain 
displays considerable sequence divergence, with ~55% pairwise identity, and only borderline homology 
with the γ -proteobacterial domains (~23% pairwise identity) is apparent (Fig. 1). The Burkholderia ColM 
Strain Origin
Accession 
number
BurM 
size (AA)
Signal 
peptide
BurM 
identity (%)
Bmi 
type
Bmi  
identity (%)
Accession 
number
Bmi size 
(AA)
bmi 
position
B. ambifaria MEX-5 Teosinte plant EDT37562 379 Tat ─ A ─ EDT37561 110 U (−)
B. glumae PG1 Unknown AJK48278 380 Tat ─ A ─ AJK48279 107 D (−)
Burkholderia sp. A1 Breeding environment of stag beetle WP_051598391 373 Sec ─ A ─ NA 107 U (−)
B. ambifaria AMMD Pea rhizosphere ABI85884 372 Sec ─ B ─ ABI85883 124 D (+ )
B. cepacia GG4 Ginger rhizosphere AFQ49511 373 / ─ B ─ AFQ49512 124 D (+ )
B. pyrrocinia CH-67 Forest soil NA 374 Tat 81.3 B 88.7 WP_017333579 124 D (+ )
Burkholderia sp. A9 Tropical soil KHK57657 373 / 99.2 B 99.2 KHK57656 124 D (+ )
B. ubonensis Bu Soil NA 379 Tat ─ B ─ WP_010092909 124 D (+ )
B. cepacia ATCC 25416 Onion AIO23154 376 Tat ─ B ─ AIO23727 132 D (+ )
B. ambifaria MC40-6 Cystic fibrosis patient ACB62834 377 Tat 84.3 B 77.3 ACB62833 131 D (+ )
B. contaminans LMG 23361 Milk of sheep with mastitis NA 377 Tat 86.7 B 75.8 KKL41098 127 D (+ )
B. oklahomensis C6786 Infected human wound AJX34277 392 Tat ─ B ─ AJX33992 111 D (+ )
B. oklahomensis EO147 Human ocular ulcer AIO69425 392 Tat 99.2 B 100 AIO69736 111 D (+ )
B. cepacia DWS 37UF10B-2 Soil KGB93731 359 Tat ─ B ─ NA 114 D (+ )
B. cepacia DWS 16B-4 Unknown KGC02247 359 Tat 96.1 B 84.3 NA 108 D (+ )
B. cenocepacia CEIB S5-1 Agricultural soil NA 359 Tat 95.3 B 82.5 NA 114 D (+ )
Table 1.  Features of characterized and hypothetical BurM bacteriocins and cognate Bmi immunity 
proteins in Burkholderia species. Protein sizes in number of amino acids (AA) include Tat- or Sec-
dependent secretory signal peptide sequences, if predicted. Highly similar BurM and Bmi subtypes are 
grouped and the pairwise AA sequence identity to a representative member of these groups (strains 
GG4, ATCC 25416, C6786, or DWS 37UF10B-2) is shown in percentage. The type of immunity protein 
(BmiA, BimB) is specified. The localization of the bmi genes is indicated by their position relative to the 
corresponding burM gene: downstream (D) or upstream (U); same strand (+ ) or opposite strand (−). NA, 
not annotated.
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modules are typified by a carboxy-terminal extension of 26–36 AA, that is absent from γ -proteobacte-
rial representatives and not part of the Pfam ColM domain (Fig. S1). Based on phylogenetic analysis 
of the ColM domains (Fig. 2), the BurMs constitute different subgroups, coinciding with the extent of 
homology between both their respective amino-terminal and carboxy-terminal parts (Table 1, Fig. S1). 
Similarly to ColM and M-type pyocins, the BurMs equally lack a defined domain in their amino-termi-
nal part. These Burkholderia proteins are further typified by a cleavable amino-terminal secretion signal 
sequence: for 12 strains, a Tat signal peptide is predicted with high probability (PRED-TAT reliability 
scores > 0.96), whereas a potential Sec signal peptide is likely present in B. ambifaria AMMD (score 
0.917) and Burkholderia sp. A1 (score 0.956). Only two proteins (nearly identical sequences of B. cepacia 
GG4 and Burkholderia sp. A9) are not classified as substrates for the Tat or Sec translocation systems 
(scores < 0.6). A Sec-type signal sequence was also observed for Burkholderia and Xanthomonas LlpA 
bacteriocins12,32, whereas this is absent from most pseudomonad counterparts33,34. At the amino-terminal 
end of the predicted mature BurM proteins, a short conserved sequence appears (Fig. 2, alignment with 
sequence logo). Although not sharing homology with colicin M’s TonB box, the high degree of conserva-
tion suggests that this region may equally represent a binding box for interaction with the Burkholderia 
TonB orthologue. The presence of a similarly positioned semi-conserved motif in syringacin M (Fig. 2) 
is required for its anti-pseudomonad activity28.
The genomic context of burM genes is not conserved but synteny is apparent within some subsets. 
In the clade comprising BurMs from strains AMMD, GG4, ATCC 25416, and Bu (Fig. 2), toxin genes 
are intertwined between genes encoding glutamate synthase and an amino acid symporter. In contrast, 
in the B. cepacia strains DWS 37UF10B-2 and DWS 16B-4, and B. cenocepacia CEIB S5–1, burM genes 
are located between a LysR family regulator and a MFS transporter. The alien nature of burM genes, that 
further seem to be unique in β -proteobacterial genera, is also underlined by an aberrant GC content. 
Whereas the Burkholderia strains have a genomic GC content of 70–75%, burM genes reside in ~2.2 kb 
stretches with a GC content of only 45–55%. In Pseudomonas, it was found that ColM-like bacteriocins 
may be present as cargo genes in tailocin clusters35,36, but this does not seem to be the case for the burk-
holderial isolates.
Purification and activity of burkhocins. Based on their disparate position in the phylogenetic tree 
and the different nature of associated putative immunity genes (see further), candidate M-type burkhocin 
genes burM1 (B. ambifaria MEX-5) and burM2 (B. ambifaria AMMD) were cloned in expression vector 
Figure 1. Multiple sequence alignment of ColM domains in selected burkhocins and characterized 
γ-proteobacterial bacteriocins. Abbreviations for species names: Bamb, Burkholderia ambifaria; Bcep, 
Burkholderia cepacia; Bglu, Burkholderia glumae; Bokl, Burkholderia oklahomensis; Bubo, Burkholderia 
ubonensis; Burk, Burkholderia sp. Previously characterized ColM domain-carrying bacteriocins are E. coli 
ColM, Pectobacterium PecMs, P. aeruginosa PaeM, P. fluorescens PfluM, and P. syringae SyrM. Shading 
reflects the degree of conservation. The conserved residues in the catalytic site are shaded in green. The 
aspartate residue that was mutated in BurM2 is marked with an asterisk.
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pET28a(+ ), generating pCMPG6228 and pCMPG6229, respectively. Fusions were created without the 
predicted secretory signal sequences to encode C-terminal His-tags, separated from the mature bacteri-
ocins by a LE (Leu-Glu) linker, in order to avoid potential interference with the (presumed) translocation 
function of the conserved amino-terminal stretch. Following expression of burM1 and burM2 in E. coli 
BL21(DE3), recombinant proteins were purified by affinity chromatography on Ni-NTA and polished by 
gel filtration (Fig. S2). Identity of the purified proteins was verified via Edman degradation, yielding the 
predicted amino-terminal sequences of mature BurM1 and BurM2 proteins.
Next, the recombinant BurMs were tested for their antagonistic potential against a panel of 44 Bcc 
strains by spotting purified bacteriocin onto a lawn of the indicator bacteria of interest. Antibacterial 
activity for BurM1 was observed for ~26% of the strains tested, whereas only ~7% of them were killed 
by BurM2 (Table S1), all of the latter set being susceptible to BurM1 as well. The lower percentage of 
BurM2 indicators identified may reflect strain bias in the test panel. In the case of BurM2, clear halos 
were obtained for only one strain (B. cenocepacia LMG 18829), whereas almost all BurM1-generated 
halos were clear (Fig.  2). Turbid halos may originate from unfavorable expression conditions for the 
Figure 2. Phylogeny of ColM domains in burkhocins and γ-proteobacterial bacteriocins. Maximum 
likelihood phylogenetic tree of ColM domains of selected Burkholderia BurMs, E. coli ColM, Pectobacterium 
PecMs, P. aeruginosa PaeM, P. fluorescens PfluM, and P. syringae SyrM. Burkholderia species abbreviations 
are the same as in Fig. 1. Bamb MEX-5 (BurM1) and Bamb AMMD (BurM2) are shown in teal and 
purple, respectively. The bacteriocin activity of BurM1 against LMG 18829 (clear halo) and of BurM2 
against LMG 18943 (turbid halo) in spot assays is illustrated. Scale bar represents 0.4 substitutions per site. 
Bootstrap values (percentages of 1000 replicates) are shown at the branches. Schematic gene organizations 
of bacteriocins and (putative) associated immunity genes are displayed next to the clades or branches 
(delimited by arcs). The arrows correspond with the gene orientations. For pectocin M2 and pseudomonad 
ColM-like bacteriocins, no adjacent immunity genes have been described. The color legend (box with scale 
bar, bottom left) describes the indicated domains and signal peptide sequences. Predicted signal sequences 
in the immunity genes, if present, are not shown. Sequence alignment of the conserved region following 
the signal sequence in BurMs and in SyrM is shown as inset (bottom right). Shading reflects the degree of 
conservation. The sequence logo graph visualizes the degree of consensus for each position.
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bacteriocin receptor at the cellular surface or poor receptor affinity. BurM1 and BurM2 were also tested 
against a selection of Pseudomonas isolates, but no strain proved to be susceptible (data not shown).
Via site-directed mutagenesis, a number of key residues (D226, Y228, D229, H235, and R236) were 
identified in the phosphatase domain of ColM22,37–39. These surface-exposed residues also occur in 
γ -proteobacterial ColM-like bacteriocins and likely facilitate binding of the targeted peptidoglycan pre-
cursors28,29,31. The equivalents of ColM residues D226 and R236 are strictly conserved in the BurM proteins 
(Fig. 1). Semi-conserved residues appear for Y228 (mainly F) and D229 (mainly D), whereas a correspond-
ing histidine is absent. To assess the significance of this conserved stretch (sequence DKFDADSSNR in 
BurM2) for burkhocin activity, we constructed a BurM2 mutant in which Asp297 (residue underlined) is 
replaced by Ala. After expression in E. coli and subsequent purification of the His-tagged protein (Fig. S2), 
this mutant form was tested for antagonistic activity against BurM2-susceptible strains. As expected, for 
all indicator strains tested, BurM2 activity was lost (data not shown).
Two sets of putative immunity genes coupled to burkhocin M genes. In addition to the burM 
genes, the low GC-content regions consistently encompass an infrequently annotated second open read-
ing frame that may represent an immunity determinant. These associated genes (bmi, burkhocin M 
immunity) are either located upstream or downstream of burM, in opposite (upstream/downstream) or 
same (downstream) orientation (Table 1, Fig. 2). The encoded gene products are of two different types 
(Fig. 3). One set of shorter proteins (BmiA group, ~106 AA), including the B. ambifaria MEX-5 poly-
peptide, harbors three predicted transmembrane helices and lacks a cleavable signal sequence for export 
(Sec or Tat) (Fig. S3). A cysteine residue in the second helix is strictly conserved but additional cysteines 
present (for instance three in the MEX-5 BmiA protein) are not. The topology prediction implies that 
only a short loop connecting the second and third helix would be exposed to the periplasmic space. A 
second type (BmiB group, ~126 AA), being more abundant, carries a single hydrophobic helix near the 
amino-terminus (Fig. S4). In about half of these (such as the B. ambifaria AMMD protein), this seg-
ment may serve as a Sec-signal peptide and be cleaved off (PRED-TAT reliability scores > 0.94). Both 
types lack the YebF domain signature (Pfam PF13995) characteristic for Cmi and structurally related 
YebF-like proteins. However, despite the absence of primary sequence homology, members of the BmiB 
group would adopt the general Cmi/YebF topology of periplasmic proteins with an amino-terminal cyto-
plasmic membrane anchor. Moreover, the presence of two perfectly conserved cysteine residues in the 
Burkholderia proteins advocates functional similarity with the Cmi immunity protein. Since the replace-
ment of the Cmi membrane anchor by a cleavable signal peptide yields a soluble periplasmic variant 
that retains protective activity23, it is possible that the BmiB proteins function in the periplasm either as 
membrane-anchored or as soluble proteins. The phylogenetic tree of this second group displays a similar 
clade topology as observed for the ColM domains of the BurMs (Fig. 2, Fig. S4). This is reminiscent of 
the coevolution observed between nuclease domains and cognate immunity proteins of S-type pyocins18 
and it supports the hypothesis that these genes may encode cognate immunity proteins.
Notably, both sets of putative immunity genes also occur as ‘orphan’ genes, at a similar – without 
associated burM – or at different genomic location in some Burkholderia. Orphan bmiA genes are very 
common among strains of the Pseudomallei group, although associated burM genes could not be iden-
tified in our study. On the other hand, Bcc strains frequently encode orphan bmiB genes. Such orphans 
can provide a reservoir of immunity and may trap trespassing bacteriocins.
Burkhocin M activity is impeded by expression of a cognate immunity gene. Associate genes 
of burM1 (bmiAMEX5) and burM2 (bmiBAMMD, with predicted Sec-signal peptide) cloned in shuttle vector 
pJB3Tc20 (pCMPG6231 and pCMPG6232, respectively) were electroporated to BurM-susceptible strains 
LMG 18830, LMG 18941, LMG 18943, and LMG 24506, and tested for BurM sensitivity via spot assay, 
using strains with empty vector as controls (Table 2). Indicator strain LMG 18829 was not suitable since 
it is resistant to high concentrations of tetracycline used as selective marker. Strains equipped with bmiA 
became fully immune to BurM1 activity at 1 mg/ml, whereas those with bmiB acquired immunity to 
Figure 3. Membrane topology of Bmi proteins from Burkholderia spp. and Cmi from E. coli. BmiA 
carries three potential transmembrane regions, whereas BmiB, like Cmi, only has one that would span 
the inner membrane (IM). In the case of certain BmiB proteins, the depicted transmembrane region may 
actually represent a Sec-dependent cleavable signal sequence. “N” denotes the amino-terminal end of the 
polypeptides.
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BurM2, at equimolar test conditions. On the contrary, bmiA was not able to provide immunity to BurM2, 
and vice versa, suggesting that both sets of BurM-associated genes act as cognate immunity partners.
Discussion
Burkholderia strains host the biosynthetic machineries for a plethora of biologically active secondary 
metabolites, including diverse molecules mediating antibiosis. Conversely, relatively few ribosomally 
encoded antimicrobial peptides and proteins have been identified in this genus9,11–13,15,16. In this study 
we characterized two members of a novel bacteriocin family (burkhocin M) in Burkholderia. Based on 
features shared with the toxins and immunity proteins of the ColM family occurring in γ -proteobacteria, 
it is anticipated that these bacteriocins affect integrity of the β -proteobacterial cell envelope by interfering 
with peptidoglycan biosynthesis. This is supported by the observation that the mutation of a conserved 
Asp residue is pivotal for obtaining a functional burkhocin M, in line with previous results for ColM and 
ColM-like bacteriocins in γ -proteobacteria. Nevertheless, the “core” residues likely interacting with lipid 
II or a related peptidoglycan precursor are not fully conserved, which may reflect differences in substrate 
specificity. In this respect, it will be of interest to elucidate whether the carboxy-terminal extension, that 
appears to be specific for the β -proteobacterial members of the ColM family, plays a role in this interac-
tion or would have a different function, for instance in receptor recognition.
Unexpectedly, we identified two independent strategies of burkhocin M immunity in Burkholderia. 
The predominant BmiB-type proteins display a similar membrane topology as Cmi, with one trans-
membrane helix and a periplasmic domain, and also carry a conserved cysteine pair. Despite the lack of 
primary sequence homology with Cmi, this suggests that BmiB proteins may adopt a similar structure 
as Cmi and inhibit the cognate burkhocins in a comparable manner as in E. coli, although the exact 
Cma-Cmi immunity mechanism yet remains to be revealed. The less abundant BmiA-type proteins rep-
resent a novel type of immunity-providing protein, predicted to contain three transmembrane helices 
and a short loop exposed to the periplasmic space. The BmiA proteins carry multiple cysteines but only 
one position appears to be perfectly conserved. Potentially, such residue may enable homodimer forma-
tion by analogy with the cysteine-mediated dimerization observed for Cmi26. Another interesting issue 
to scrutinize is how protection can be provided by the integral BmiA-type proteins. Here, focus would 
be on the role of the periplasm-exposed loop that is envisaged to interact with a burkhocin.
Following the identification of a lectin-like bacteriotoxin12, this new bacteriocin family further adds 
to the diversity of these narrow-spectrum antibacterials, and constitutes another example of Burkholderia 
bacteriocins that are shared with γ -proteobacteria.
Materials and Methods
Bacterial strains and media. Burkholderia strains (Belgian Co-ordinated Collections of Micro-
organisms) used in this study are listed in Table S1. Burkholderia and E. coli strains were routinely grown 
in LB broth (2.5%, MP Biomedicals) at 37 °C, with shaking at 200 rpm. Media were solidified with agar 
(1.5%, Invitrogen) and supplemented with filter-sterilized isopropyl-β -D-thiogalactopyranoside (IPTG, 
25 μ g/mL, ForMedium), ampicillin (100 μ g/mL, Sigma-Aldrich), kanamycin (50 μ g/mL, Sigma-Aldrich), 
Indicator strain Immunity gene BurM1 (MEX-5) BurM2 (AMMD)
LMG 18830
Control + ─ 
bmiAMEX-5 ─ ─ 
bmiBAMMD + ─ 
LMG 18941
Control + T
bmiAMEX-5 ─ T
bmiBAMMD + ─ 
LMG 18943
Control + T
bmiAMEX-5 ─ T
bmiBAMMD + ─ 
LMG 24506
Control + ─ 
bmiAMEX-5 ─ ─ 
bmiBAMMD + ─ 
Table 2.  Heterologous expression of bmi genes in burkhocin-susceptible strains. Selected Bcc strains 
were transformed with shuttle vector pJB3Tc20 (control, no insert), or with pJB3Tc20-derived plasmids 
equipped with different bmi genes, and tested for susceptibility to BurM1 and BurM2 via spot assay. + , clear 
halo; T, turbid halo: reduced cell density compared to cell lawn; −, no growth inhibition of the indicator 
strain.
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or tetracycline (150 μ g/mL, Sigma-Aldrich) when required. Bacterial strains were kept on plate at 4 °C, 
or stored at − 80 °C in glycerol (25% v/v, Sigma-Aldrich).
DNA methods and plasmid construction. Genomic DNA from Burkholderia spp. was isolated 
using the Puregene Yeast/Bact. Kit B (Qiagen). Genes encoding putative bacteriocins in Burkholderia 
ambifaria were amplified by polymerase chain reaction with Q5 DNA polymerase (BIOKÉ), with a 
C1000 Thermal Cycler (Bio-Rad), using genomic DNA as a template. PCR amplicons were purified 
with the QIAquick PCR Purification Kit (Qiagen), digested with NcoI/XhoI (Roche Diagnostics), ligated 
in pET28a(+ ) using T4 DNA ligase (Invitrogen), and transformed to E. coli TOP10F’. Transformants 
were verified for the presence of inserts by PCR with Taq polymerase (BIOKÉ). Primers used for PCR 
amplification are listed in Table S2. Insert-confirmed plasmids were collected with the QIAprep Spin 
Miniprep Kit (Qiagen) and validated by sequencing (GATC Biotech, Constance, Germany). Bacteriocin 
genes were cloned without their predicted amino-terminal secretory signal sequences, with the His6-tag 
located at the carboxy-terminus (terminal sequence LEHHHHHH). Constructed plasmids were 
pCMPG6228 (BamMEX5DRAFT_6664 from B. ambifaria MEX-5, GenBank EDT37562; BurM1) and 
pCMPG6229 (BAMB_RS01670 from B. ambifaria AMMD, GenBank ABI85884; BurM2). In the case of 
BAMB_RS01670, the gene was first cloned in pUC18, using primers PGPRB-10167 and PGPRB-10168 
(digested with PstI and XbaI, Roche Diagnostics). The internal NcoI restriction site was removed via 
DpnI-mediated (Roche Diagnostics) site-directed mutagenesis, using PGPRB-10117 and PGPRB-10118. 
Sequence-confirmed plasmid DNA was used as a template for amplification and subsequent pET28a 
cloning, as described above. A D297A mutant (position according to numbering in full-length precur-
sor) in BurM2 was equally constructed via DpnI-mediated site-directed mutagenesis (primers in Table 
S2), using pCMPG6229 as a template, resulting in pCMPG6230. Sequence confirmed pET expression 
plasmids were transformed to E. coli BL21(DE3) via heat shock transformation.
Similarly, putative immunity genes from B. ambifaria MEX-5 (BamMEX5DRAFT_6663, GenBank 
EDT37561) and B. ambifaria AMMD (BAMB_RS01665, GenBank AJY23231) were PCR amplified 
(including the respective upstream ribosome binding sites), digested with PstI/XbaI and SphI/BamHI, 
respectively, ligated in shuttle vector pJB3Tc20, transformed to E. coli TOP10F’ and insert verified via 
sequencing. Resulting plasmids were pCMPG6231 and pCMPG6232, respectively. All plasmids used in 
this study are listed in Table S2.
Overexpression and purification of recombinant B. ambifaria BurM proteins. Recombinant 
His-tagged BurM1 and BurM2 were generated in E. coli BL21(DE3) carrying the plasmids pCMPG6228 
and pCMPG6229, respectively. 1-mL volumes of overnight cultures were transferred to 500 mL LB 
and incubated at 37 °C until an OD600 of 0.7. Then IPTG was added at a final concentration of 1 mM 
and cultures were incubated at 20 °C for 16 hours, shaking at 200 rpm. Next, cells were harvested in a 
Beckman X-15R (20 min, 5000 g) and kept overnight at − 20 °C. Following day, cell pellets were thawed, 
resuspended in lysis buffer (300 mM NaCl, 50 mM NaH2PO4, 10 mM imidazole, pH 8.0) and disrupted 
by sonication using a Branson Digital Sonifier 250 (amplitude 18%, 8 cycles of 30 sec on/off). Next, 
protein extracts were treated with benzonase (0.01 U/μ L, 37 °C, 1 hour; Sigma-Aldrich) and cleared via 
centrifugation (25 min, 10000 g) and filtering (0.25 μ m, MilliPore). Presence of recombinant proteins was 
verified by SDS-PAGE and subsequent coomassie blue staining. Next, protein extracts were applied on 
a 5-mL HisTrap column (GE Healthcare) and purified by nickel affinity chromatography, using an Äkta 
Purifier (GE Healthcare). Bound proteins were eluted with a linear gradient of 10–500 mM imidazole in 
lysis buffer and verified for purity by SDS-PAGE. Selected elution fractions were dialyzed to TRIS buffer 
(20 mM, 200 mM NaCl, pH 7.5) and polished by gel filtration chromatography on a Superdex 200 pg 
16/60 column (1 ml/min, GE Healthcare), using the TRIS buffer as running buffer. The same expression 
and purification procedure was followed for the generation of BurM2 mutant protein.
The concentration of purified proteins was estimated by absorbance measurement at 280 nm with 
a Spectronic Genesys 6 (Thermo). Molar extinction coefficients were 45,840 mol/L−1 cm−1 for BurM1 
(37,663 Da), 49,975 mol/L−1 cm−1 for BurM2 (37,626 Da) and 49,975 mol/L−1 cm−1 for the D297A 
mutant protein (37,582 Da)40. Amino-terminal amino acid (AA) sequences of PVDF-blotted recom-
binant proteins were determined via Edman degradation, using a Procise 491 cLC protein sequencer 
(Applied Biosystems).
Bacteriocin spot assay. Antagonistic activity of purified recombinant proteins was determined by a 
spot assay test. LB plates were overlaid with 5 mL of soft agar (0.5%), seeded with 50 μ L of an indicator 
culture (16 hours, ~109 CFU/ml) to generate a bacterial cell lawn. 10-μ L spots of purified recombinant 
protein (20 μ M) were applied on the plates. TRIS buffer was used as a negative control. After drying, 
plates were incubated overnight at 37 °C and scored the following day for the presence of zones of growth 
inhibition (halos).
Electroporation of pJB3Tc20-derived plasmids to Burkholderia spp. Electrocompetent 
Burkholderia cells were prepared as described previously with minor modifications41. Briefly, 1-mL 
volumes of overnight cell cultures were centrifuged (3 min, 5000 g), supernatants removed and cells 
washed twice with 1 mL of 300 mM sucrose (VWR International), and finally resuspended in 50 μ L 
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sucrose solution. Cells were immediately used for electroporation. 2 μ L of purified plasmid pJB3Tc20, 
pCMPG6231 or pCMPG6232 was added to the competent cells. These suspensions were transferred to 
2 mm cuvettes (Eurogentec) and electroporated with a Biorad Gene Pulser, at 2.5 kV, 25 μ F and 200 Ω . 
Subsequently, the electroporated cells were incubated for one hour at 37 °C prior to plating on LB sup-
plemented with tetracycline.
Phylogenetic analysis. Putative ColM-like proteins in Burkholderia genomes were identified using 
the National Center for Biotechnology (NCBI) non-redundant database, via Blast searches. Sequences of 
ColM catalytic domains in E. coli, Pectobacterium and Pseudomonas were used as search queries (Pfam 
PF14859). Similarly, Burkholderia genomes were searched for ColM-like immunity proteins (YebF-like 
proteins, Pfam PF13995). Multiple sequence alignments were generated with MUSCLE and phylogenetic 
analysis with PhyML, implemented in the Geneious v7.1.2. software. Amino-terminal signal sequences 
were predicted by PRED-TAT42 (http://www.compgen.org/tools/PRED-TAT). Transmembrane regions 
and topology were predicted by TMHMM (http://www.cbs.dtu.dk/services/TMHMM).
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